Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

29.6%

45 terminated/withdrawn out of 152 trials

Success Rate

52.6%

-33.9% vs industry average

Late-Stage Pipeline

12 trials in Phase 3/4

Results Transparency

114%

57 of 50 completed trials have results

Key Signals

32 recruiting57 with results34 terminated11 withdrawn

Enrollment Performance

Analytics

N/A

43(36.8%)

Phase 2

29(24.8%)

Phase 1

28(23.9%)

Phase 3

9(7.7%)

Early Phase 1

5(4.3%)

Phase 4

3(2.6%)

117Total

N/A(43)

Phase 2(29)

Phase 1(28)

Phase 3(9)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (152)

Showing 20 of 152 trials

NCT03209713Not ApplicableActive Not Recruiting

Edtech-HPV: A Community Approach Using Education and Technology to Increase HPV Vaccination

Role: collaborator

NCT06575894Not ApplicableEnrolling By Invitation

Implementing Mental Health Programs Across Communities in Iowa & Indiana for Transformation

Role: lead

NCT03719079Terminated

Nanowear Heart Failure Management Multi-sensor Algorithm

Role: collaborator

NCT01453101Phase 2Completed

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Role: lead

NCT01453140Phase 1Terminated

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

Role: lead

NCT01241734Phase 1Completed

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL

Role: lead

NCT02338232Not ApplicableTerminated

Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

Role: lead

NCT01242267Phase 1Completed

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT

Role: lead

NCT03586297Completed

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

Role: lead

NCT01659606Phase 2Active Not Recruiting

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

Role: collaborator

NCT02446236Phase 1Active Not Recruiting

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Role: lead

NCT01453088Phase 2Terminated

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Role: lead

NCT07011342Not ApplicableRecruiting

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

Role: lead

NCT06987708Not ApplicableNot Yet Recruiting

Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers

Role: lead

NCT06798558Phase 2Recruiting

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

Role: lead

NCT07214688Phase 2Recruiting

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

Role: lead

NCT01297764Phase 1Active Not Recruiting

A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Role: lead

NCT06052449Not ApplicableCompleted

Assessing Social Determinants of Health to Increase Cancer Screening

Role: lead

NCT01366612Phase 3Terminated

PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

Role: lead

NCT02697396Active Not Recruiting

Trial of a Social Marketing Campaign to Increase HPV Vaccination Among Mexican American Children

Role: collaborator